title: Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis.
abstract: OBJECTIVE
  To assess the correlation between advanced non-small cell lung cancer (NSCLC) with or without pulmonary lymphangitic carcinomatosis (PLC) and fluorodeoxyglucose (FDG) uptake and its effect on survival outcomes.
  
  
  METHODS
  We retrospectively reviewed 157 patients with NSCLC. The mean and maximum standardized uptake values (SUVmean and SUVmax, respectively), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were evaluated for their effect on overall survival (OS) and progression-free survival (PFS).
  
  
  RESULTS
  The PLC group included 55 patients and the non-PLC group included 102 patients. The SUVmean, SUVmax, MTV and TLG values were lower in the non-PLC group. In the PLC group, primary lung tumor TLG was a significant predictor of PFS, while whole-body TLG was found to be a significant predictor in non-PLC patients.
  
  
  CONCLUSIONS
  Primary lung tumor TLG was a good predictor in PLC patients. Whole-body TLG could be a useful predictor only in patients without PLC.
authors.affiliation: Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C. Department of Preventive Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C. School of Medicine, Tzu Chi University, Hualien, Taiwan, R.O.C. Divisions of Pulmonology and Critical Care, Department of Internal Medicine, Dalin Tzu Chi Hospital, Dalin, Taiwan, R.O.C. Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan, R.O.C.
authors.forename: Hean
authors.initials: H
authors.lastname: Ooi
authors.affiliation: Department of Nuclear Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
authors.forename: Ching-Yuan
authors.initials: CY
authors.lastname: Chen
authors.affiliation: Department of Nuclear Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
authors.forename: Yu-Chun
authors.initials: YC
authors.lastname: Hsiao
authors.affiliation: Departments of Nuclear Medicine, Taipei Veterans General Hospital and Tri-Service General Hospital, Taipei City, Taiwan, R.O.C. wshuang01@gmail.com bthsieh@ctust.edu.tw.
authors.forename: Wen-Sheng
authors.initials: WS
authors.lastname: Huang
authors.affiliation: Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C. wshuang01@gmail.com bthsieh@ctust.edu.tw.
authors.forename: Bor-Tsung
authors.initials: BT
authors.lastname: Hsieh
mesh_terms: D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000150:complications / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D000072078:Positron Emission Tomography Computed Tomography; D011379:Prognosis; D047368:Tumor Burden
chemical_list: D019788:Fluorodeoxyglucose F18
keywords: Lung cancer; fluorodeoxyglucose; prognosis; pulmonary lymphangitic carcinomatosis